$614 Million is the total value of SPHERA FUNDS MANAGEMENT LTD.'s 107 reported holdings in Q3 2016. The portfolio turnover from Q2 2016 to Q3 2016 was 60.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| TEVA | Sell | TEVA PHARMACEUTICAL INDS LTDadr | $18,496,000 | -38.6% | 402,000 | -33.0% | 3.01% | -61.5% |
| AGN | Sell | ALLERGAN PLC | $16,122,000 | -26.6% | 70,000 | -26.3% | 2.62% | -53.9% |
| BIIB | Sell | BIOGEN INC | $15,652,000 | +28.2% | 50,000 | -1.0% | 2.55% | -19.6% |
| CLCD | Sell | COLUCID PHARMACEUTICALS INC | $15,260,000 | +273.5% | 400,000 | -20.0% | 2.48% | +134.2% |
| ITRN | Sell | ITURAN LOCATION AND CONTROL | $12,083,000 | +15.6% | 456,668 | -0.8% | 1.97% | -27.5% |
| CELG | Sell | CELGENE CORP | $11,498,000 | -24.8% | 110,000 | -29.0% | 1.87% | -52.8% |
| GILD | Sell | GILEAD SCIENCES INC | $8,917,000 | -44.5% | 112,700 | -41.5% | 1.45% | -65.2% |
| MYL | Sell | MYLAN N V | $7,624,000 | -29.5% | 200,000 | -20.0% | 1.24% | -55.8% |
| FOLD | Sell | AMICUS THERAPEUTICS INC | $6,697,000 | +22.1% | 905,000 | -10.0% | 1.09% | -23.5% |
| Sell | NEURODERM LTD | $4,687,000 | +11.6% | 253,513 | -1.9% | 0.76% | -30.1% | |
| GWPH | Sell | GW PHARMACEUTICALS PLCads | $4,115,000 | +12.3% | 31,000 | -22.5% | 0.67% | -29.5% |
| CLSD | Sell | CLEARSIDE BIOMEDICAL INC | $3,923,000 | +86.5% | 226,100 | -24.6% | 0.64% | +17.0% |
| GNCA | Sell | GENOCEA BIOSCIENCES INC | $3,119,000 | +7.3% | 609,271 | -14.1% | 0.51% | -32.7% |
| AAP | Sell | ADVANCE AUTO PARTS INC | $2,173,000 | -51.4% | 14,569 | -47.3% | 0.35% | -69.5% |
| ADRO | Sell | ADURO BIOTECH INC | $1,740,000 | -9.5% | 140,000 | -17.6% | 0.28% | -43.3% |
| KERX | Sell | KERYX BIOPHARMACEUTICALS INC | $1,655,000 | -55.6% | 311,600 | -44.6% | 0.27% | -72.2% |
| SHPG | Sell | SHIRE PLCsponsored adr | $1,454,000 | -93.3% | 7,500 | -97.2% | 0.24% | -95.8% |
| ONS | Sell | ONCOBIOLOGICS INC | $850,000 | -3.5% | 200,000 | -22.8% | 0.14% | -39.7% |
| INSYQ | Exit | INSYS THERAPEUTICS INC NEW | $0 | – | -16,407 | -100.0% | -0.06% | – |
| SCYX | Exit | SCYNEXIS INC | $0 | – | -128,500 | -100.0% | -0.07% | – |
| CYTK | Exit | CYTOKINETICS INC | $0 | – | -32,069 | -100.0% | -0.08% | – |
| ABEO | Exit | ABEONA THERAPEUTICS INC | $0 | – | -138,105 | -100.0% | -0.08% | – |
| CERU | Exit | CERULEAN PHARMA INC | $0 | – | -450,000 | -100.0% | -0.25% | – |
| SERV | Exit | SERVICEMASTER GLOBAL HLDGS I | $0 | – | -27,750 | -100.0% | -0.29% | – |
| PTCT | Exit | PTC THERAPEUTICS INC | $0 | – | -174,461 | -100.0% | -0.32% | – |
| VRX | Exit | VALEANT PHARMACEUTICALS INTL | $0 | – | -68,500 | -100.0% | -0.36% | – |
| BLUE | Exit | BLUEBIRD BIO INC | $0 | – | -40,000 | -100.0% | -0.45% | – |
| CYNA | Exit | CYNAPSUS THERAPEUTICS INC | $0 | – | -134,037 | -100.0% | -0.58% | – |
| RLYP | Exit | RELYPSA INC | $0 | – | -130,000 | -100.0% | -0.62% | – |
| CLVS | Exit | CLOVIS ONCOLOGY INC | $0 | – | -200,000 | -100.0% | -0.71% | – |
| Exit | ALDER BIOPHARMACEUTICALS INC | $0 | – | -112,500 | -100.0% | -0.73% | – | |
| Exit | GW PHARMACEUTICALS PLCcall | $0 | – | -310 | -100.0% | -0.74% | – | |
| Exit | SAGE THERAPEUTICS INCcall | $0 | – | -1,000 | -100.0% | -0.78% | – | |
| RDUS | Exit | RADIUS HEALTH INC | $0 | – | -90,000 | -100.0% | -0.86% | – |
| Exit | ALNYLAM PHARMACEUTICALS INCput | $0 | – | -600 | -100.0% | -0.86% | – | |
| BCOMF | Exit | B COMMUNICATIONS LTD | $0 | – | -148,861 | -100.0% | -0.92% | – |
| Exit | TESARO INCcall | $0 | – | -450 | -100.0% | -0.98% | – | |
| Exit | ACHAOGEN INC | $0 | – | -1,257,366 | -100.0% | -1.24% | – | |
| Exit | ACADIA HEALTHCARE COMPANY INcall | $0 | – | -1,500 | -100.0% | -1.26% | – | |
| Exit | ALEXION PHARMACEUTICALS INC | $0 | – | -42,323 | -100.0% | -1.28% | – | |
| VRTX | Exit | VERTEX PHARMACEUTICALS INC | $0 | – | -57,600 | -100.0% | -1.29% | – |
| RARE | Exit | ULTRAGENYX PHARMACEUTICAL IN | $0 | – | -105,000 | -100.0% | -1.33% | – |
| Exit | BIOGEN INCput | $0 | – | -250 | -100.0% | -1.57% | – | |
| GSK | Exit | GLAXOSMITHKLINE PLCsponsored adr | $0 | – | -398,287 | -100.0% | -1.66% | – |
| Exit | AMGEN INC | $0 | – | -85,000 | -100.0% | -3.36% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEVA PHARMACEUTICAL-SP ADR | 36 | Q3 2023 | 8.4% |
| MERCK & CO INC NEW | 35 | Q3 2023 | 8.4% |
| NICE Systems Ltd | 27 | Q3 2023 | 4.4% |
| BIOGEN INC | 26 | Q3 2023 | 6.7% |
| AMICUS THERAPEUTICS INC | 26 | Q2 2022 | 4.3% |
| PFIZER INC | 25 | Q3 2023 | 9.2% |
| SAREPTA THERAPEUTICS INC | 25 | Q3 2023 | 3.2% |
| JOHNSON & JOHNSON | 24 | Q3 2023 | 8.0% |
| UNIQURE NV | 23 | Q3 2023 | 1.2% |
| SYNDAX PHARMACEUTICALS INC | 22 | Q3 2023 | 3.9% |
View SPHERA FUNDS MANAGEMENT LTD.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Cyclacel Pharmaceuticals, Inc. | February 06, 2023 | 250,000 | 2.0% |
| Altimmune, Inc. | February 14, 2022 | 1,244,241 | 3.1% |
| Allot Ltd. | February 16, 2021 | 1,129,054 | 3.2% |
| Larimar Therapeutics, Inc. | February 16, 2021 | ? | ? |
| Neos Therapeutics, Inc. | February 16, 2021 | ? | ? |
| Orgenesis Inc. | February 16, 2021 | 525,216 | 0.0% |
| Sio Gene Therapies Inc. | February 16, 2021 | ? | ? |
| X4 Pharmaceuticals, Inc | February 16, 2021 | 250,000 | 0.0% |
| Axovant Gene Therapies Ltd. | February 25, 2020 | 2,931,017 | 8.0% |
| Axovant Gene Therapies Ltd. | February 11, 2020 | 398,540 | 1.8% |
View SPHERA FUNDS MANAGEMENT LTD.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR/A | 2024-02-15 |
| 13F-HR | 2024-02-14 |
| SC 13G | 2024-02-08 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-10 |
| SC 13G | 2023-08-30 |
View SPHERA FUNDS MANAGEMENT LTD.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.